section name header

Pronunciation

rye-boe-SYE-klib

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Indications

High Alert

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 66% absorbed following oral administration.

Distribution: Extensively distributed to the tissues.

Metabolism/Excretion: Mostly metabolized in the liver by the CYP3A4 isoenzyme; 17% excreted unchanged in feces, 12% in urine.

Half-life: 32 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1–4 hrunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema, QT interval prolongation, syncope.

Derm: alopecia, pruritus, rash, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN).

F and E: hypokalemia, hypophosphatemia.

GI: liver enzymes, abdominal pain, constipation, diarrhea, nausea, stomatitis, vomiting, hyperbilirubinemia.

GU: serum creatinine, fertility (males).

Hemat: anemia, neutropenia, thrombocytopenia.

Metab: appetite.

MS: back pain.

Neuro: fatigue, headache, insomnia.

Resp: dyspnea, INTERSTITIAL LUNG DISEASE (ILD).
Misc: fever.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

Renal Impairment

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Kisqali